{
  "id": 15466699,
  "title": "StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics",
  "url": "https://urgent.news/2026/10/18/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-18T18:33:31.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/drug-discovery/stockwatch-liquidia-rebounds-after-settling-legal-wrangle-with-united-therapeutics/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Liquidia rebounded after settling a legal dispute with United Therapeutics, which had caused its stock to lose more than half its value. The settlement ended six lawsuits involving patent infringement, trade secrets, and antitrust claims between the companies. Liquidia agreed to pay $380.7 million to United Therapeutics and remove pulmonary hypertension associated with interstitial lung disease as an indication for its sole commercial product Yutrepia. Despite the setback, analysts view the settlement as favorable for Liquidia, with Jefferies raising its price target by 22% to $55.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}